NCT01675570View on ClinicalTrials.gov

A Study of RX-10045 in the Treatment of Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Dry Eye Syndrome
Interventions
DRUG

RX-10045

One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.

DRUG

Vehicle for RX-10045

One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.

Trial Locations (1)

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

C.T. Development America, Inc.

INDUSTRY

NCT01675570 - A Study of RX-10045 in the Treatment of Dry Eye Disease | Biotech Hunter | Biotech Hunter